Risk factors for atherosclerotic vascular disease

Handbook of Experimental Pharmacology

Volumn 170, Issue , 2005, Pages 71-105

  Von Eckardstein, A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

C reactive protein; Diabetes mellitus; Family history; Fibrinogen; Framingham score; Gene; Global risk estimation; Guidelines; HDL cholesterol; Homocysteine; Hypertension; LDL cholesterol; Lipoprotein(a); Obesity; Overweight; PROCAM algorithm; Risk factor; Triglycerides

Indexed keywords

EID: 85099486493     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-27661-0_2     Document Type: Article

References (127)

1. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL (2002) Elevated fibrinogen and homocysteine levels enhance the risk ofmortality in patients froma high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 22:1042-1045
2. Albert MA, Glynn RJ, Ridker PM (2003) Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108:161-165
3. Alberti KGMM, Zimmet PZ for the WHO consultation (1998) Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetes Med 15:539-553
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002a) Major outcomes inmoderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002b) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997
6. Anonymous (1995) Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346:1647-1653
7. Anonymous (1996) Hypertension Control Report of a WHO Expert Committee. WHO Technical Report Series No. 862, World Health Organization, Geneva
8. Anonymous (1997a) The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure. Arch InternMed 157:2413-2446
9. Anonymous (1997b) The Expert Committee on the Diagnosis and Classification of Diabetes mellitus:Report of the ExpertCommittee on theDiagnosis andClassification ofDiabetes mellitus. Diabetes Care 20:1183-1197
10. Anonymous (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497
11. Anonymous (2002) Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Final reportNational Cholesterol Education Program Heart, Lung and Blood Institute, National Institutes of Health NIH Publication No. 02-5215 September 2002 (http://www.nhlbi.nih.gov/guidelines/cholesterol)
12. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD (2000) Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 36:1253-1260
13. AradY, SpadaroLA,GoodmanK,Lledo-Perez A, ShermanS,LernerG, et al. (1996)Predictive valueof electronbeamcomputed tomographyof the coronary arteries. 19-month followup of 1173 asymptomatic subjects. Circulation 93:1951-1953
14. Ariyo AA, Thach C,TracyR, CardiovascularHealth Study Investigators (2003) Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 349:2108-2115
15. Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310-315
16. Austin MA,Hokanson JE, Edwards KL (1998)Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B
17. Becker CR, Kleffel T, Crispin A, Knez A, Young J, Schoepf UJ, et al. (2001) Coronary artery calcium measurement: agreement of multirow detector and electron beam CT. Am J Roentgenol 176:1295-1298
18. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T (1997) Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 52:254-261
19. Bobak M, Hense HW, Kark J, Kuch B, Vojtisek P, Sinnreich R, Gostomzyk J, Bui M, von Eckardstein A, Junker R, Fobker M, Schulte H, Assmann G, Marmot M (1999) An ecological study of determinants of coronary heart disease rates: a comparison of Czech, Bavarian and Israeli men. Int J Epidemiol 28:437-444
20. Bolibar I, von Eckardstein A, Assmann G, Thompson S (2000) Short-term prognostic value of lipid measurements in patientswith angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb.Haemost 84:955-960
21. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS (1999) Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 19:1992-1997
22. Bots ML, Grobbee DE (2002) Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther 16:341-351
23. Brown MS, Goldstein JL (1992) Kochs postulates for cholesterol. Cell 71:187-188
24. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM (2004) Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 350:1495-1504
25. Collins R, Armitage J, Parish S, SleighP, PetoR, HeartProtectionStudyCollaborativeGroup (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
26. CollinsR,Armitage J, Parish S, Sleight P, PetoR;Heart Protection StudyCollaborativeGroup (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
27. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM; SCORE project group (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987-1003
28. Cullen P, Funke H (2001) Implications of the human genome project for the identification of genetic risk of coronary heart disease and its prevention in children. Nutr Metab Cardiovasc Dis 11 (Suppl 5):45-51
29. Cullen P, Schulte H,AssmannG(1997) TheMunsterHeart Study (PROCAM): totalmortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 96:2128-2136
30. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease.Meta-analysis of prospective studies. Circulation 102:1082-1085
31. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387-1397
32. De Backer G, De Bacquer D, Kornitzer M (1998) Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis 137 (Suppl):S1-S6
33. DeBacker G,Ambrosioni E,Borch-JohnsonK,BrotonsC, CifkovaR,Dallongeville J,Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomson T,Wood D (2003) European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur Heart J 24:1601-1610 (http://www.escardio.org)
34. DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303
35. DetranoRC,WongND, DohertyTM,ShavelleRM,TangW, GinztonLE, et al. (1999)Coronary calciumdoes not accurately predict near-termfuture coronary events in high-risk adults. Circulation 99:2633-2638
36. Folsom AR (2001) Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 86:366-373
37. Fruchart JC, Brewer HB, Jr., Leitersdorf E (1998) Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 81:912-917
38. Genest JJ, McNamara JR, Salem DN, Schaefer EJ (1991) Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 67:1185-1189
39. Goldstein JL, Hobbs HH, Brown MS (2001) Familial Hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2863-2915
40. Gordon DJ, Rifkind BM (1989) High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321:1311-1316
41. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA,Watson DJ, Downs JR, de Cani JS (2000) Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484
42. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy:Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49-57
43. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW (2003) Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290:891-897
44. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V (1999) AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals fromthe AmericanHeartAssociation and the American College of Cardiology. J Am Coll Cardiol 34:1348-59
45. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239
46. Gupta R, Birnbaum Y, Uretsky BF (2004) The renal patient with coronary artery disease: current concepts and dilemmas. J Am Coll Cardiol 44:1343-1353
47. Hackam DG, Anand SS (2003) Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 290:932-940
48. Hayward CS, Kelly RP, Collins P 2000 The roles of gender, the menopause and hormone replacement on cardiovascular function. Cardiovasc Res 46:28-49
49. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
50. Hense HW, Schulte H, Lowel H, Assmann G, Keil U (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany-results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24:937-945
51. Hergenc G, Schulte H, Assmann G, von Eckardstein A (1999) Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis 145:147-156
52. Hersberger M, von Eckardstein A (2003) Low high density lipoprotein cholesterol -physiological background, clinical importance and drug treatment. Drugs 63:1907-1945
53. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End Stage Disease (PREVEND)StudyGroup (2002)Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106:1777-1782
54. Hirano K, Yamashita S, Kuga Y, Sakai N, Nozaki S, Kihara S, Arai T, Yanagi K, Takami S, Menju M (1995) Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15:1849-1856
55. Hu FB, Willett WC (2002) Optimal diets for prevention of coronary heart disease. JAMA 288:2569-2578
56. Humphries SE, Ridker PM, Talmud PJ (2004) Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscler Thromb Vasc Biol 24:628-636
57. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2522
58. International Task Force for Prevention of Coronary Heart Disease (1998) Coronary heart disease: Reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. NutrMetab Cardiovasc Dis 8:205-271
59. International Task Force for Prevention of Coronary Heart Disease (2002) Pocket Guide to Prevention of Coronary heart disease. http://www.chd-taskforce. de/guide.htm
60. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD (1989) Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910
61. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in theCopenhagenMale Study. Circulation 97:1029-1036
62. KhotUN, Khot MB, Bajzer CT, Sapp SK,Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ (2003) Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290:898-904
63. Kopelman PG (2002) Obesity as a medical problem. Nature 404:635-643
64. Koenig W (2003) Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89:601-609
65. Koenig W, Lowel H, Baumert J, Meisinger C (2004) C-reactive protein modulates risk prediction based on the Framingham Score. Implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109:1349-1353)
66. Krantz DS, McCeney MK (2002) Effects of psychological and social factors on organic disease: a critical assessment of research on coronary heart disease. Annu Rev Psychol 53:341-369
67. Kromhout D, Menotti A, Kesteloot H, Sans S (2002) Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation 105:893-898
68. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H (1999) The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027-1036
69. Lamarche B, Lemieux I, Despres JP (1999) The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 25:199-211
70. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH (2004) Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350:2673-2681
71. Ledue TB, Rifai N (2003) Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 49:1258-1271
72. Li S, ChenW, Srinivasan SR, BondMG, Tang R, Urbina EM, Berenson GS (2003) Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA 290:2271-2276
73. Liu PY, Death AK, Handelsman DJ (2003) Androgens and cardiovascular disease. Endocr Rev 24:313-340
74. Lloyd-Jones DM, Larson MG, Beiser A, Levit D (1999) Lifetime risk of developing coronary heart disease. Lancet 353:89-92
75. Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, Fruchart JC, Ducimetiere P (2002) Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol 22:1155-1161
76. Mahley RW, Rall SC (2001) Type III Hyperlipoproteinemia (Dysbetalipoproteinemia). In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 2835-2862
77. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH (1992) Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85:37-45
78. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, Couderc R, Dati F, Rifai N, Sakurabayashi I, Tate JR, Steinmetz A (2000) Use of a reference material proposed by the International Federation of Clinical Chemistry and LaboratoryMedicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 46:1956-1967
79. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S (2003) Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 49:1785-1796
80. McGillHC Jr,McMahanCA(2003) Starting earlier to prevent heart disease. JAMA290:2320-2322
81. McKechnie R, Mosca L (2003) Physical activity and coronary heart disease: prevention and effect on risk factors. Cardiol Rev 11:21-25
82. Miller M, Seidler A,Moalemi A, Pearson TA (1998) Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 31:1252-1257
83. Mukamal KJ, Rimm EB (2001) Alcohols effects on the risk for coronary heart disease. Alcohol Res Health 25:255-261
84. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, Rimm EB (2003) Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348:109-118
85. Mungall MM, Gaw A, Shepherd J (2003) Statin therapy in the elderly: does it make good clinical and economic sense? Drugs Aging 20:263-275
86. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J (2004) The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 140: 9-17
87. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein A (1999) Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 94:3678-3682
88. Palinski W, Napoli C (2002) The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J 16:1348-1360
89. Parving HH, Hovind P (2002) Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep 4:387-393
90. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499-511
91. PepysMB,HirschfieldGM(2003) C-reactive protein: a critical update. JClin Invest 111:1805-1812
92. Pontremoli R, Leoncini G, Ravera M, Viazzi F, Vettoretti S, Ratto E, Parodi D, Tomolillo C, Deferrari G (2002) Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 13 (Suppl 3):S169-S172
93. Prichard SS (2003) Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 14(9 Suppl 4):S315-S320
94. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS (2003) Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 290:2277-2283
95. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-369
96. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
97. Ridker PM, RifaiN,ClearfieldM, Downs JR,Weis SE,Miles JS,GottoAMJr,Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators (2001) Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965
98. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565
99. Rimm EB, Stampfer MJ (2002) Wine, beer, and spirits: are they really horses of a different color? Circulation 105:2806-2807
100. Rohrer L,Hersberger M, von Eckardstein A (2004)High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15:269-278)
101. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J (1999): Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
102. Scheuner MT (2001) Genetic predisposition to coronary artery disease. Curr Opin Cardiol 16:251-260
103. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, Meier B, Turi ZG, Hess OM (2001) Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 345:1593-1600
104. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM (2002a) Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 288:973-979
105. Schnyder G, Flammer Y, Roffi M, Pin R, Hess OM (2002b) Plasma homocysteine levels and late outcome after coronary angioplasty. J Am Coll Cardiol 40:1769-1776
106. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, OBrien E, Ostergren J, ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 361:1149-1158
107. SharrettAR,BallantyneCM,Coady SA,Heiss G, SorliePD,CatellierD, PatschW(2001)Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein( a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108-1113
108. Shepherd J (2003) Preventing the next event in the elderly: the PROSPER perspective. Atheroscler Suppl 4:17-22
109. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group (2002) PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623-1630
110. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB (2000) Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283:1845-1852
111. Sing CF, Stengard JH, Kardia SL (2003) Genes, environment, and cardiovascular disease. Arterioscler Thromb Vasc Biol 23:1190-1196
112. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH (1991) A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325:373-381
113. Strater R, Becker S, von Eckardstein A,Heinecke A, Gutsche S, Junker R, Kurnik K, Schobess R, Nowak-Gottl U (2002) Prospective assessment of risk factors for recurrent stroke during childhood-a 5-year follow-up study. Lancet 360:1540-1545
114. Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ (2001) Low serum cholesterol and haemorrhagic stroke in men:KoreaMedical InsuranceCorporation Study. Lancet 357:922-925
115. Tsimikas S, Witztum JL (2002) Shifting the diagnosis and treatment of atherosclerosis to children and young adults: a new paradigm for the 21st century. J Am Coll Cardiol 40:2122-2124
116. van derMeer IM, deMaat MP, Kiliaan AJ, van der Kuip DA, Hofman A,Witteman JC (2003) The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163:1323-1328
117. von Eckardstein A (2004) Is there a need for novel cardiovascular risk factors? Nephrol Dial Transpl 19:761-765)
118. von Eckardstein A, Assmann G (2000) Prevention of coronary heart disease by raising high-density lipoprotein cholesterol? Curr Opin Lipidol 11:627-637
119. von Eckardstein A, Schulte H, Assmann G (1999): Increased risk ofmyocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 99:1925
120. von Eckardstein A, Schulte H, Cullen P, Assmann G (2001) Lipoprotein(a) further increases the risk of coronary events in menwith high global cardiovascular risk. JAmColl Cardiol 37:434-439
121. von Eckardstein A, Schulte H, Assmann G (2005) Vergleich internationaler Konsensus-Empfehlungen zur Erkennung des präsymptomatischen Hochrisikopatienten für den Herzinfarkt in Deutschland. Z. Kardiologie 94:52-60
122. Voss R, Cullen P, Schulte H, Assmann G (2002) Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 31:1253-1262
123. Wilson PW, DAgostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847
124. Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM (2000) Coronary artery calcium evaluation by electron beam computed tomography and its relation to new cardiovascular events. Am J Cardiol 86:495-498
125. Writing Group for theWomens Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Womens Health Initiative randomised controlled trial. JAMA 288:321-333
126. Wu FCW, von Eckardstein A (2003) Androgens and coronary artery disease. Endocrine Rev 24:183-217
127. YerkeyMW,Kernis SJ, Franklin BA, SandbergKR,McCullough PA(2004).Renal dysfunction and acceleration of coronary disease. Heart 90:961-966